scholarly journals Management of Chronic Daily Headache with Focus on Botulinum Toxin Type A

2020 ◽  
Vol 1 (2) ◽  
pp. 38-42
Author(s):  
Kadyrkhodjayeva N ◽  
Prokhorova A
Keyword(s):  
Botulinum Toxin ◽  
Pain Relief ◽  
Chronic Daily Headache ◽  
Classical Method ◽  
Botulinum Toxin A ◽  
Complete Relief ◽  
Percent Reduction ◽  
Group I ◽  
Daily Headache ◽  
Group Ii

Aim: The purpose of the study was to review the efficacy, safety, and tolerability of botulinum toxin A (BTX-A) as a prophylactic treatment in adults with chronic daily headache (CDH). Material and methods: The research participated in 100 patients with CDH comparing two groups of patients. Group I, 54 patients (31 women and 23 men) treated by BTX-A and group II, 46 patients (27 women and 21 men) treated with the classical method, with an average age of 35 ± 9 years. The patient’s condition in group I was assessed on the third day, on the 7th day and the 15th day after the BTX-A injection and assessed every 15 days for 3 months, in group II the patients were evaluated every 15 days. Results: After 3 months headache severity in group I: 2 (3,7%) patients had no changes, 7 (12,9%) patients with less than 50 percent reduction in pain, 23 (42,6%) reported 70 to 95 percent pain relief, and 22 (40,8%) had complete relief. Group II: 12 (26,1%) patients had no changes, 16 (34,8%) patients with less than 50 percent reduction in pain, 10 (21,7%) reported 70 to 95 percent pain relief, and 8 (17,4%) had complete relief. The mean change from baseline frequency of headaches ranged from 3 ± 1 headaches per 30‐day periods in-group I and 7 ± 2 headaches in group II. The patient’s in-group I used painkillers for an acute headache 4 ± 1 day, compared to 10 ± 2 days for the group II per 30-day period. Conclusion: In this study, BTX-A injections are safe, well-tolerated, not any treatment-related serious adverse events reported. BTX-A injections recommended optimizing clinical outcomes for patients with CDH without using other prophylactic medications. Although, further observations are needed.

scholarly journals A prospective randomized double blind placebo controlled crossover study of fluoxetine efficacy in the prophylaxis of chronic daily headache in children and adolescents

2005 ◽  
Vol 63 (3a) ◽  
pp. 559-563 ◽  
Author(s):  
José Luiz Dias Gherpelli ◽  
Sandro Blasi Esposito
Keyword(s):  
Adverse Effects ◽  
Crossover Study ◽  
Children And Adolescents ◽  
Chronic Daily Headache ◽  
Headache Frequency ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Group I ◽  
Daily Headache ◽  
Group Ii

Thirty-two children (21 female and 11 male), between 7 and 14 years old, with chronic daily headache (CDH) were consecutively included in a prospective, randomized, double blind, placebo controlled crossover study. The patients were divided in group I (fluoxetine vs. placebo), with 17 patients and group II (placebo vs. fluoxetine), with 15 patients. After one month of baseline headache frequency recording, the patients received fluoxetine in dosages from 0.25 to 0.50 mg/kg for three months. A wash out period of one month was followed by another three months treatment period. Results showed a significant decrease in headache frequency in the study period [78% reduction in group I (p<0.025), and 45% reduction in group II (p=0.025)]. Gastrointestinal adverse effects were observed in nine patients (29%) that received fluoxetine, compared with 3 (10%), with placebo. We conclude that fluoxetine efficacy is not higher than placebo in the prophylaxis of CDH in children and adolescents.

Botulinum Toxin a for Chronic Daily Headache: A Randomized, Placebo-Controlled, Parallel Design Study

Cephalalgia ◽  
2004 ◽  
Vol 24 (1) ◽  
pp. 60-65 ◽  
Author(s):  
WG Ondo ◽  
KD Vuong ◽  
HS Derman
Keyword(s):  
Botulinum Toxin ◽  
Chronic Daily Headache ◽  
Botulinum Toxin A ◽  
Botulinum Toxin Type A ◽  
A Priori ◽  
Cumulative Effect ◽  
Botulinum Toxin Type ◽  
Open Label ◽  
Double Blind ◽  
Daily Headache

Sixty patients with headaches of more than 15 days per month were recruited for this double-blind, placebo-controlled, parallel study of botulinum toxin type A (BTX) for chronic tension type and chronic migraine headaches. The primary efficacy point was the number of headache-free days as assessed by diary for 12 weeks after BTX injection. Secondary efficacy points included global impressions, the use of abortive headache medications, and palpation. After recruitment, subjects kept diaries for 4 weeks prior to randomization, at which time they received either 200 U of BTX or matching placebo and were followed. After the week-12 evaluation, patients were offered 200 U of BTX (open label), and were similarly followed for another 12 weeks. The mean days with headache of the 60 subjects (49 female, mean age 47 ± 11 years) was 23 ± 7 out of 30. Both groups were demographically similar (58 completed). Over a 12-week period after injections, headache-free days had improved in the BTX group from week 8 to 12 ( P < 0.05), and strongly tended to improve over the entire 12-week period, 33 ± 23 vs. 24 ± 16 days without headache ( P = 0.07), but did not meet the a priori significance criteria. The subject global impressions ( P < 0.05), subject change in headache impressions ( P < 0.005), and investigator global impressions ( P < 0.001) all improved in the BTX group compared with placebo. Adverse events were mild and did not differ between groups. At week 24 (open label), headache-free days were less in the twice BTX injected group compared with the once injected group, 40 ± 26 vs. 26 ± 19 ( P < 0.05). BTX may help chronic daily headache and appears to have a cumulative effect with subsequent injections. The treatment was very well tolerated.

Evaluation of the rivastigmine role against botulinum toxin-A-induced osteoporosis in albino rats: A biochemical, histological, and immunohistochemical study

2018 ◽  
Vol 37 (12) ◽  
pp. 1323-1335 ◽  
Author(s):  
DM Ali ◽  
WY Abdelzaher ◽  
SMN Abdel-Hafez
Keyword(s):  
Bone Marrow ◽  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Physiological Saline ◽  
Compact Bone ◽  
Albino Rats ◽  
Toxin A ◽  
Group Iii ◽  
Group I ◽  
Factor Α

The present study aimed to evaluate the role of rivastigmine against the effect of a single unilateral botulinum toxin-A (BTX-A) injection on the bone and bone marrow of adult albino rats 4 weeks after injection. Twenty-four Wistar albino rats were divided into four equal groups: group I, which received distilled water; group II, which received rivastigmine (0.3 mg/kg daily, intraperitoneally for 4 weeks); group III, which received BTX-A (4 IU in 0.2 mL physiological saline) single dose, intramuscularly; and group IV, which received BTX-A + rivastigmine. The results revealed that BTX-A induced a significant decrease in the calcium level with a significant increase in the phosphorus, alkaline phosphatase, C-reactive protein, and tumor necrosis factor α levels in serum. Furthermore, a significant increase in malondialdehyde with a significant decrease in reduced glutathione activities in both bone and bone marrow. Histologically, a distortion and thinning out of the compact bone and trabeculae of cancellous bone of the rat femur in the BTX-A group with an increase in adipocytes in adjacent bone marrow were detected. Immunohistochemically, Cluster of Differentiation 68 (CD68) showed a significant increase in both osteoclasts and bone marrow macrophage. Rivastigmine treatment could relieve the toxic effects induced by BTX-A. In conclusion, rivastigmine has a protective effect against the hazardous effects of BTX-A on bone and bone marrow.

scholarly journals Evaluation of the Treatment of Frozen Shoulder by Hydraulic Distention Under

2010 ◽  
Vol 15 (1) ◽  
Author(s):  
Shakeel Khan Ghauri ◽  
Muhammad Aftab Anwar ◽  
Asif Hanif ◽  
Muhammad Akram
Keyword(s):  
Pain Relief ◽  
Local Anesthesia ◽  
Glenohumeral Joint ◽  
Frozen Shoulder ◽  
Muscle Relaxants ◽  
Early Results ◽  
Group I ◽  
Normal Sleep ◽  
Group Ii

Objective:  To evaluate the result of treatment of frozen shoulder by Hydraulic Distention under local anesthesia with steroid and intra-articular steroid alone. Study Design:  It was a prospective and comparative study. Samples size:  60 patients were taken in this study and were divided into two groups. Duration and Setting:  The study was conducted in 2000 - 2001  treated in the department of Orthopaedic, Mayo Hospital Lahore. Methodology:  The patients were divided into two groups. Group-I were treated by hydraulic distension of glenohumeral joint with 50 ml normal saline under local anesthesia with steroid followed by medicines (oral analgesics and muscle relaxants) and exercises. Patients in group-II were treated by intra-articular steroid followed by medicines (oral analgesics and muscle relaxants) and exercises. Results:  The average age of patients in group I was 52 ± 2.16 years and 50 ± 2.03 in group II. There were 37 (63%) females and 22 (37%) males in our study. Female to male ratio was 1.7:1. All patients in group-I noted immediate pain relief with excellent return of range of motion (ROM) and resumption of normal sleep. At the end of 45 days of follow up all patients had returned to their normal daily activities. Most of them got excellent ROM and pain relief. All patients in group-II noted immediate pain relief and resumption of almost normal sleep. At the end of 45 days of follow up most of the patient presented with good relief of pain but could not return to most of their normal activities because of less improvement in ROM. Conclusions:  Hydraulic distension technique is a quick, safe and gives early results, so it should be considered first for the treatment of frozen shoulder. Key Words:  Frozen Shoulder, Hydrologic Distention, Intra articular steroid.

scholarly journals COMPARATIVE ANALYSIS OF SURFACE ELECTROMYOGRAPHY DATA IN PATIENTS WITH CHRONIC DAILY HEADACHE AFTER BOTULOTOXIN INJECTION TYPE A AND STANDARD MEDICAL THERAPY

InterConf ◽  
2021 ◽  
pp. 377-386
Author(s):  
Anna Prokhorova
Keyword(s):  
Medical Therapy ◽  
Chronic Daily Headache ◽  
Surface Electromyography ◽  
Type A ◽  
Surface Emg ◽  
Standard Medical Therapy ◽  
Group I ◽  
Significant Difference ◽  
Before And After ◽  
Daily Headache

Goal. The aim of the study was to compare the results of surface electromyography after injection of Botulinum toxin type A and standard medical therapy. Material and methods. The study encompassed 62 participants with chronic daily headaches (CDH). Group I included 26 patients with chronic migraine (15 treated with BTX-A injection and 11 treated with standard medical therapy), whilst, Group II comprised of 36 patients with chronic tension type headache (20 treated with BTX-A injection and 16 treated with standard medical therapy) with an average age of 32.1 ± 10.3 (M ± SD) years. Before and after therapy, clinical questionnaires, instrumental data, and headache episode characteristics were collected from all patients. To examine the differences between BTX - A injection and standard medical therapy, we measured muscle activity with surface EMG in patients with chronic daily headache before and after 3 months of treatment. On days when the patients had no headache attacks, the surface EMG was measured. Results. After treatment, surface electromyography data revealed a statistically significant difference in outcomes between the patients who received BTX-A injection and those who received standard medical therapy. Before treatment on surface EMG, all patients with chronic daily headache had high amplitude and velocity in the muscles under study, and there was no statistically significant difference between these groups, where p => 0.05. In this study, it was discovered that there was no statistically significant difference in pericranial and neck muscles dysfunction (before treatment between patients receiving BTX-A injection and standard medical therapy in Group I, patients with CM 95% CI -0.9087 - 0.4887; t = -0.607, df = 40, p = 0.5470 and Group II, patients with CTTH 95 % CI -0.5756 - 0.4356, t = -0.27, After treatment, there was a statistically significant difference between groups treated by BTX- A injection and standard medical therapy, with CM 95% CI 0.3258 - 1.4142, t = 3.231, df = 40, p = 0.0025 and CTTH 95 % CI 0.1020 - 1.1780, t = 2.381, df = 58, p = 0.0206, where p = <0.05. Conclusion. The obtained results testify the effectiveness of BTX-A injections compared to standard medical therapy in patients with CDH.

scholarly journals Botulinum toxin type a for the treatment of spasticity in children with cerebral palsy

2007 ◽  
Vol 64 (8) ◽  
pp. 513-518 ◽  
Author(s):  
Lidija Dimitrijevic ◽  
Ivona Stankovic ◽  
Vesna Zivkovic ◽  
Aleksandra Mikov ◽  
Hristina Colovic ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Range Of Motion ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Group I ◽  
Active Range Of Motion ◽  
Significant Difference ◽  
Motor Outcome ◽  
Group Ii

Background/Aim. Cerebral palsy (CP) is the most common physical disability in childhood. Children have problems with motor functions as a result of limbs spasticity, which leads to severe contractures and limbs deformity. There is a growing interest in the therapeutic role of botulinum toxin type A (BTA) in CP. The aim of this study was to examine the effects of BTA on spasticity, active range of motion and functional motor outcomes in children with CP. Methods. This study included 42 children of both sexes, aged 2?6 years, with spastic CP, divided into two groups: group I (21 child) treated with BTA and physical therapy, and group II (21 child) treated with physical therapy only. The following parameters were analyzed: spasticity; active range of motion of the hip, knee and ankle, and functional motor outcome. These parameters measurements were carried out four times in both groups: before the treatment, three, eight and 16 weeks after the beginning of the treatment. The obtained results were statistically processed and compared. Results. There was no evidence of any significant difference between the groups before the treatment. After eight weeks there was a remarkable difference concerning spasticity reducing on behalf of the group I (group I - 0.76?0.51 vs. II group - 2.17?0.64; p < 0.0001). There was statistically significant difference concerning active range of motion increasing on behalf of the group I (hip abduction: group I - 44.37?1.130 vs. group II - 32.61?8,070, p < 0,01; knee extension: group I - 0,77?1.820 vs. II group - 14.99?7.610, p < 0.01; dorsiflexion of the foot: group I - 11.50?6.080 vs. group II - 8.98?7.850, p < 0,01). A statistically significant difference was found after 16 weeks in functional motor outcome as well, on behalf of the group I: functional motor abilities level in the group I was 1.86 vs. 2.71 in the group II, p < 0.05. Conclusion. Botulinum toxin type A application leads to an important spasticity decreasing, active range of motion increasing, as well as to functional abilities in children with CP. .

Sign in / Sign up

Export Citation Format

Share Document